Olanzapine (Zyprexa):charactirestics of a new antipsychotic
- 1 November 1997
- journal article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 6 (11) , 1743-1752
- https://doi.org/10.1517/13543784.6.11.1743
Abstract
Olanzapine is a thienobenzodiszepine antipsychotic,which exerts broad-spectrum receptor antagonism in the central nervous system.It demonstrates regionally selective dopamine antagonist activity as measured with the depolarisation block model and fos activation paradigm. Early in vivo imaging studies suggest a relatively low D2 occupancy in th striatum (69%) with a higher 5-HT2 occupancy in the cortex (84%) of 10 mg.Its pharmaco-kinetics are dose-proportional; Tmax is 5 h and the elimination half-life is 31 h (range:21-54 h). Efficacy studies show equivalent antipsychotic efficacy to haloperidol with the possibility of superior efficacy on negative symptoms and depression. Motor side-effects are minimal with mild akathisia emerging at the highest doses; non-motor side-effects are also minimal. Olanzapine is a highly effective antipsychotic drug with minimal side-effects. It will be an important new drug for treating schizophrenia.Keywords
This publication has 17 references indexed in Scilit:
- Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor bindingPsychopharmacology, 1996
- Electrophysiological Effects of Olanzapine, a Novel Atypical Antipsychotic, on A9 and A10 Dopamine NeuronsNeuropsychopharmacology, 1996
- Radioreceptor Binding Profile of the Atypical Antipsychotic OlanzapineNeuropsychopharmacology, 1996
- Effects of Olanzapine on Regional C-Fos Expression in Rat ForebrainNeuropsychopharmacology, 1996
- Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapinePsychopharmacology, 1995
- Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liabilityPsychopharmacology, 1995
- SchizophreniaNew England Journal of Medicine, 1994
- Clozapine for the Treatment-Resistant SchizophrenicArchives of General Psychiatry, 1988
- Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic DrugsScience, 1976
- Effect of Chlorpromazine or Haloperidol on Formation of 3‐Methoxytyramine and Normetanephrine in Mouse BrainActa Pharmacologica et Toxicologica, 1963